Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...

Today, Henlius is a fully integrated biopharmaceutical company with dozens of clinical-phase candidates racing to join its biosimilar version of MabThera on the market. Fosun Pharma and a team of ...

Today, Henlius is a fully integrated biopharmaceutical company with dozens of clinical-phase candidates racing to join its biosimilar version of MabThera on the market. Fosun Pharma and a team of ...

Roche’s Mabthera (rituximab) blood cancer and inflammatory diseases drug faces cheaper competition for the first time in Europe after regulators approved a near-copy, or biosimilar, from Celltrion.